PT  - JOURNAL ARTICLE
AU  - Taubel, Jorg
AU  - Cole, Samuel Thomas
AU  - Spencer, Christopher S.
AU  - Freier, Anne
AU  - Camilleri, Dorothée
AU  - Lorch, Ulrike
TI  - Why the SARS-CoV-2 antibody test results may be misleading: insights from a longitudinal analysis of COVID-19
AID  - 10.1101/2020.12.08.20245894
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.08.20245894
4099  - http://medrxiv.org/content/early/2020/12/11/2020.12.08.20245894.1.short
4100  - http://medrxiv.org/content/early/2020/12/11/2020.12.08.20245894.1.full
AB  - To estimate the effectiveness of vaccines in development, a robust mechanism is required to understand immunity, risks of reinfection and measure the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and how this may change over time. This study is a longitudinal analysis of COVID-19 infection rates using PCR, membrane immunoassay and chemiluminescent microparticle immunoassay (CMIA) diagnostic tests. Our data confirm that antibody levels wane in the three months after symptom onset. Comparison of the three methods used suggests that quantitative CMIA testing may exaggerate numbers of COVID-19 negative individuals.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRAS ID: 281788Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This brief report communicates results taken from a study reviewed and given favourable opinion by NRES Committee (West Midlands - Edgbaston).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request.